A Plasma-based Deep Proteomic Platform for early-stage Breast Cancer Detection

Area of Science:

• Proteomics
• Biomarker Discovery
• Oncology

Background:

• Mammography accuracy is limited in certain populations, like women with dense breasts.
• Liquid biopsies offer a potential complementary screening approach.
• Early detection of breast cancer is crucial for improved patient outcomes.

Purpose of the Study:

• To develop and validate a plasma-based protein classifier for early-stage breast cancer detection.
• To assess the classifier's performance across different breast densities.
• To evaluate the utility of plasma proteomics in breast cancer screening.

Main Methods:

• A case-control study involving 116 early-stage breast cancer patients and 219 healthy controls.
• Plasma samples analyzed using label-free mass spectrometry (MS)-based proteomics.
• Machine learning algorithms employed for classifier development and validation (LOOCV).

Main Results:

• The classifier achieved an Area Under the Curve (AUC) of 0.96.
• Sensitivity was 86.2% and specificity was 90.4%.
• High sensitivity (>85%) was maintained across low and high breast density groups at 90% specificity.

Conclusions:

• Plasma proteomics can serve as a powerful diagnostic tool for early-stage breast cancer.
• The developed classifier demonstrates high accuracy and potential for clinical application.
• This approach shows promise in overcoming limitations of conventional breast cancer screening methods.